Bortezomib Use in MCL
In this phase III trial, 487 patients with newly diagnosed mantle cell lymphoma who were not eligible or not considered for stem-cell transplantation were randomised to receive R-CHOP or VR-CAP.
There was a relative improvement of 59%. On the basis of investigator assessment, the median durations of progression-free survival were 16.1 months and 30.7 months, respectively (HR, 0.51; p <0.001), a relative improvement of 96%. However, rates of neutropenia and thrombocytopenia were higher in the VR-CAP group. Read more here.